SK1652004A3 - Použitie inhibítorov fosfodiesterázy IV - Google Patents

Použitie inhibítorov fosfodiesterázy IV Download PDF

Info

Publication number
SK1652004A3
SK1652004A3 SK165-2004A SK1652004A SK1652004A3 SK 1652004 A3 SK1652004 A3 SK 1652004A3 SK 1652004 A SK1652004 A SK 1652004A SK 1652004 A3 SK1652004 A3 SK 1652004A3
Authority
SK
Slovakia
Prior art keywords
ethyl
dihydro
tetrahydropyridazin
dimethoxyphenyl
methoxyphenyl
Prior art date
Application number
SK165-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Hans-Michael Eggenweiler
Michael Wolf
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7702358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK1652004(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK1652004A3 publication Critical patent/SK1652004A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK165-2004A 2001-10-12 2002-09-19 Použitie inhibítorov fosfodiesterázy IV SK1652004A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10150517A DE10150517A1 (de) 2001-10-12 2001-10-12 Verwendung von Phosphodiesterase IV-Inhibitoren
PCT/EP2002/010507 WO2003032993A1 (de) 2001-10-12 2002-09-19 Verwendung von phosphodiesterase iv - inhibitoren

Publications (1)

Publication Number Publication Date
SK1652004A3 true SK1652004A3 (sk) 2005-05-05

Family

ID=7702358

Family Applications (1)

Application Number Title Priority Date Filing Date
SK165-2004A SK1652004A3 (sk) 2001-10-12 2002-09-19 Použitie inhibítorov fosfodiesterázy IV

Country Status (15)

Country Link
US (1) US20040235845A1 (zh)
EP (1) EP1435958A1 (zh)
JP (1) JP2005505604A (zh)
KR (1) KR20050028900A (zh)
CN (1) CN1564687A (zh)
AR (1) AR037741A1 (zh)
AU (1) AU2002338734B2 (zh)
CA (1) CA2460135C (zh)
CZ (1) CZ2004457A3 (zh)
DE (1) DE10150517A1 (zh)
HU (1) HUP0401641A3 (zh)
MX (1) MXPA04002639A (zh)
NO (1) NO20041938L (zh)
SK (1) SK1652004A3 (zh)
WO (1) WO2003032993A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002521A (es) * 2003-09-05 2006-06-20 Altana Pharma Ag Uso de inhibidores de pde4 para el tratamiento de diabetes mellitus.
EP1716123A1 (en) * 2004-02-04 2006-11-02 Altana Pharma AG Pyridazinone derivatives and their use as pde4 inhibitors
JP4778449B2 (ja) 2004-02-04 2011-09-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−（ピペリジン−４−イル）−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
EA015382B1 (ru) 2005-03-08 2011-08-30 Никомед Гмбх Применение рофлумиласта для лечения сахарного диабета типа 2
DE102005055355A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
BR112017001334A2 (pt) 2014-08-06 2017-11-14 Pfizer compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
RU2626677C1 (ru) * 2016-03-09 2017-07-31 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение фармацевтической композиции 2-морфолино-5-фенил-6н-1,3,4-тиадиазина с аскорбиновой кислотой в качестве средства коррекции аллоксанового сахарного диабета

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134893A1 (de) * 1991-10-23 1993-04-29 Merck Patent Gmbh Thiadiazinone
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
DE19514568A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
GB9525262D0 (en) * 1995-12-11 1996-02-07 Bayer Ag Heterocyclylcarbonyl substituted benzofuranyl-ureas
DE19604388A1 (de) * 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives

Also Published As

Publication number Publication date
DE10150517A1 (de) 2003-04-17
AU2002338734B2 (en) 2007-11-08
AR037741A1 (es) 2004-12-01
CA2460135C (en) 2010-08-24
JP2005505604A (ja) 2005-02-24
US20040235845A1 (en) 2004-11-25
MXPA04002639A (es) 2004-06-07
WO2003032993A1 (de) 2003-04-24
CN1564687A (zh) 2005-01-12
EP1435958A1 (de) 2004-07-14
KR20050028900A (ko) 2005-03-23
HUP0401641A3 (en) 2007-02-28
CA2460135A1 (en) 2003-04-24
CZ2004457A3 (cs) 2005-04-13
HUP0401641A2 (hu) 2004-11-29
NO20041938L (no) 2004-05-11

Similar Documents

Publication Publication Date Title
ES2526675T3 (es) N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
ES2533065T3 (es) Bencenosulfonamidas útiles como inhibidores de los canales de sodio
EP2468732B1 (en) 1H-Quinazoline-2,4-diones
ES2348999T3 (es) Derivados de tiadiazol para el tratamiento de enfermedades neurodegerativas.
RU2269519C2 (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
FI90235C (fi) Menetelmä eläinlääketieteellisesti käyttökelpoisten -aryyli-4-(4,5-dihydro-3,5-diokso-1,2,4-triatsin-2(3H)-yyli)bentseeniasetonitriilien valmistamiseksi
SK1652004A3 (sk) Použitie inhibítorov fosfodiesterázy IV
DE19632549A1 (de) Arylalkanoylpyridazine
CN102652135A (zh) 脂肪酸酰胺水解酶的含氮杂环抑制剂
SK287362B6 (sk) Derivát arylalkanoylpyridazínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
RU2161613C2 (ru) Арилалкилтиадиазиноны, способ их получения, фармацевтическая композиция
ZA200104269B (en) 4,5-azolo-oxindoles.
JPS6351328A (ja) 脳細胞保護作用を有する医薬組成物
CA2700539A1 (en) Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity
SK1892004A3 (en) Substituted alkaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
DE19915364A1 (de) Verwendung von Arylalkanoylpyridazinen
JPS60246377A (ja) 新規な複素環化合物を含有する組成物
JP7324930B2 (ja) カルバメート置換スチリルスルホン類化合物及びその製造方法ならびにその使用
EP0405905A2 (en) Use of Isoxazolin-3-one Derivatives as antidepressants
KR20040028916A (ko) 소듐/칼슘 교환 시스템을 저해하는 약제
JP4198755B6 (ja) アリールアルカノイルピリダジン誘導体
JP2002308774A (ja) Ｉｖ型ホスホジエステラーゼ選択的阻害剤
EP0107536A1 (fr) Benzo-et thiéno-triazine-1,2,3 ones-4, procédés de préparation et médicaments les contenant
ES2526982T3 (es) N-Sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
US5262413A (en) Use of isoxazolin-3-one derivatives as antidepressants

Legal Events

Date Code Title Description
FC9A Refused patent application